Phibro Animal Health (PAHC) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 95.2% versus a gain of 0.3%. Over five years, TEVA leads with a +304.8% price change compared with +73.0% for PAHC. Teva Pharmaceutical Industries is the larger company by market cap ($45.89 billion vs $1.50 billion), about 30.5 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (9.6x vs 12.7x for Teva Pharmaceutical Industries). Phibro Animal Health pays a dividend yielding 1.30%, while Teva Pharmaceutical Industries does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAHC | TEVA |
|---|---|---|
| Share price | $37.02 | $39.35 |
| Market cap | $1.50B | $45.89B |
| 1-day change | -1.86% | +0.43% |
| YTD return | +0.96% | +25.54% |
| 1-year return | +0.27% | +95.22% |
| 5-year return | +73.03% | +304.75% |
| P/E ratio (TTM) | 15.23 | 65.58 |
| Forward P/E | 9.64 | 12.73 |
| EPS (TTM) | $2.43 | $0.60 |
| Dividend yield | 1.30% | 0.00% |
| Annual dividend | $0.48 | $0.00 |
| Revenue (latest FY) | — | $17.26B |
| Revenue growth (YoY) | — | +4.32% |
| Net income (latest FY) | — | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | — | 12.50% |
| Net margin | — | 8.17% |
| 52-week high | $60.08 | $40.79 |
| 52-week low | $28.25 | $18.83 |
| Distance from 52-week high | -38.38% | -3.53% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +18.85% | +15.12% |
| Average volume | 235.16K | 5.29M |
| Shares outstanding | 21.11M | 1.17B |
| Employees | 2,605 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 30.5 times larger than Phibro Animal Health by market value ($45.89B vs $1.50B).
- TEVA has outperformed PAHC by 95.0 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.6x vs 15.2x trailing P/E).
- Phibro Animal Health offers a meaningfully higher dividend yield (1.30% vs 0.00%).
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
PAHC vs TEVA FAQ
Which is bigger, Phibro Animal Health or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.89B compared with $1.50B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, PAHC or TEVA?
TEVA returned +95.22% over the past 12 months, compared with +0.27% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PAHC or TEVA?
PAHC has the lower trailing P/E at 15.2, versus 65.6 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Phibro Animal Health or Teva Pharmaceutical Industries?
Phibro Animal Health pays a dividend yielding 1.30%, while Teva Pharmaceutical Industries does not currently pay a regular dividend.
Are Phibro Animal Health and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.